The US Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) are extending telehealth flexibilities that allow providers to.
DEA and SAMHSA issued a temporary rule extending telemedicine flexibilities adopted during the COVID-19 public health emergency. Current flexibilities that allow providers to prescribe certain controlled substances via telemedicine will continue through November 11, 2023.
DEA proposed rules to make permanent telemedicine flexibilities used during COVID 19. Specifically, telemedicine prescribing of certain controlled substances without an in person medical examination and expansion of buprenorphine prescribing via telemedicine encounters.
On February 24, 2023, the federal Drug Enforcement Administration (DEA) issued a pair of proposed rules to make permanent certain “telemedicine flexibilities” related to the prescribing.